Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Victor Vaughn sold 5,750 shares of the stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $45.03, for a total transaction of $258,922.50. Following the transaction, the vice president now directly owns 15,094 shares of the company’s stock, valued at $679,682.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Victor Vaughn also recently made the following trade(s):

  • On Tuesday, January 9th, Victor Vaughn sold 15,000 shares of Supernus Pharmaceuticals stock. The stock was sold at an average price of $42.04, for a total transaction of $630,600.00.
  • On Tuesday, January 2nd, Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock. The stock was sold at an average price of $40.11, for a total transaction of $2,206,050.00.

Shares of Supernus Pharmaceuticals Inc (SUPN) traded down $1.40 during trading on Tuesday, reaching $42.75. 746,600 shares of the company’s stock were exchanged, compared to its average volume of 589,500. Supernus Pharmaceuticals Inc has a 12 month low of $23.10 and a 12 month high of $50.04. The stock has a market capitalization of $2,260.00, a PE ratio of 38.86 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals’s revenue for the quarter was up 41.5% on a year-over-year basis. analysts expect that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Teachers Advisors LLC increased its holdings in Supernus Pharmaceuticals by 6.9% in the second quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock valued at $20,087,000 after buying an additional 29,939 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Supernus Pharmaceuticals by 790.8% during the 2nd quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock worth $11,699,000 after purchasing an additional 240,978 shares in the last quarter. First Trust Advisors LP purchased a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $2,255,000. State Street Corp increased its stake in shares of Supernus Pharmaceuticals by 3.1% during the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after purchasing an additional 42,165 shares in the last quarter. Finally, Pictet Asset Management Ltd. increased its stake in shares of Supernus Pharmaceuticals by 438.7% during the 3rd quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock worth $19,651,000 after purchasing an additional 400,083 shares in the last quarter. 98.22% of the stock is owned by institutional investors.

Several research analysts recently issued reports on SUPN shares. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. FBR & Co started coverage on shares of Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $53.00 price target for the company. Janney Montgomery Scott raised shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price target for the company in a report on Monday, December 4th. Stifel Nicolaus raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a report on Tuesday, November 7th. Finally, Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $49.90.

TRADEMARK VIOLATION WARNING: “Insider Selling: Supernus Pharmaceuticals Inc (SUPN) VP Sells 5,750 Shares of Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/16/insider-selling-supernus-pharmaceuticals-inc-supn-vp-sells-5750-shares-of-stock.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.